Based upon our initial evaluation of CTA gene induction with HMAs, we elected to further examine induced NY-ESO-1 and MAGEA3/A6 expression in a larger cohort of AML patients as these genes are established tumor antigens with clinically translatable vaccines in development. This evidence concerns the gene MAGEA3 and acute myeloid leukemia.